Table of Contents Author Guidelines Submit a Manuscript
Journal of Thyroid Research
Volume 2011 (2011), Article ID 958626, 13 pages
http://dx.doi.org/10.4061/2011/958626
Review Article

Thyroid Hormone and Cardiac Disease: From Basic Concepts to Clinical Application

1Department of Pharmacology, University of Athens, 11527 Athens, Greece
2CNR Institute of Clinical Physiology and Fondazione CNR-Regione Toscana G. Monasterio, Pisa, Italy

Received 11 January 2011; Revised 16 March 2011; Accepted 20 March 2011

Academic Editor: Michelina Plateroti

Copyright © 2011 Iordanis Mourouzis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Taegtmeyer, S. Sen, and D. Vela, “Return to the fetal gene program: a suggested metabolic link to gene expression in the heart,” Annals of the New York Academy of Sciences, vol. 1188, pp. 191–198, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Pantos, I. Mourouzis, and D. V. Cokkinos, “New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider?” Heart Failure Reviews, vol. 16, no. 1, pp. 79–96, 2011. View at Publisher · View at Google Scholar
  3. Y.-K. Lee, K.-M. Ng, Y.-C. Chan et al., “Triiodothyronine promotes cardiac differentiation and maturation of embryonic stem cells via the classical genomic pathway,” Molecular Endocrinology, vol. 24, no. 9, pp. 1728–1736, 2010. View at Publisher · View at Google Scholar
  4. B. Swynghedauw, “Molecular mechanisms of myocardial remodeling,” Physiological Reviews, vol. 79, no. 1, pp. 215–262, 1999. View at Google Scholar · View at Scopus
  5. M. Rajabi, C. Kassiotis, P. Razeghi, and H. Taegtmeyer, “Return to the fetal gene program protects the stressed heart: a strong hypothesis,” Heart Failure Reviews, vol. 12, no. 3-4, pp. 331–343, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Pantos, I. Mourouzis, A. Dimopoulos et al., “Enhanced tolerance of the rat myocardium to ischemia and reperfusion injury earlyafter acute myocardial infarction,” Basic Research in Cardiology, vol. 102, no. 4, pp. 327–333, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Pantos, I. Mourouzis, T. Saranteas et al., “Thyroid hormone receptors α1 and β1 are downregulated in the post-infarcted rat heart: consequences on the response to ischaemia-reperfusion,” Basic Research in Cardiology, vol. 100, no. 5, pp. 422–432, 2005. View at Publisher · View at Google Scholar
  8. S. J. Odelberg, “Inducing cellular dedifferentiation: a potential method for enhancing endogenous regeneration in mammals,” Seminars in Cell and Developmental Biology, vol. 13, no. 5, pp. 335–343, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Sánchez Alvarado, “Regeneration in the metazoans: why does it happen?” BioEssays, vol. 22, no. 6, pp. 578–590, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. E. R. Porrello, A. I. Mahmoud, E. Simpson et al., “Transient regenerative potential of the neonatal mouse heart,” Science, vol. 331, no. 6020, pp. 1078–1080, 2011. View at Publisher · View at Google Scholar
  11. N. J. Oviedo and W. S. Beane, “Regeneration: the origin of cancer or a possible cure?” Seminars in Cell and Developmental Biology, vol. 20, no. 5, pp. 557–564, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. J. F. Gudernatsch, “Feeding experiments on tadpoles—I: the influence of specific organs given as food on growth and differentiation. A contribution to the knowledge of organs with internal secretion,” Development Genes and Evolution, vol. 35, no. 3, pp. 457–483, 1912. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Paris, F. Brunet, G. V. Markov, M. Schubert, and V. Laudet, “The amphioxus genome enlightens the evolution of the thyroid hormone signaling pathway,” Development Genes and Evolution, vol. 218, no. 11-12, pp. 667–680, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. M. W. Slack, G. Lin, and Y. Chen, “Molecular and cellular basis of regeneration and tissue repair: the Xenopus tadpole: a new model for regeneration research,” Cellular and Molecular Life Sciences, vol. 65, no. 1, pp. 54–63, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Chassande, “Do unliganded thyroid hormone receptors have physiological functions?” Journal of Molecular Endocrinology, vol. 31, no. 1, pp. 9–20, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Sato, D. R. Buchholz, B. D. Paul, and Y. B. Shi, “A role of unliganded thyroid hormone receptor in postembryonic development in Xenopus laevis,” Mechanisms of Development, vol. 124, no. 6, pp. 476–488, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. J. D. Furlow and E. S. Neff, “A developmental switch induced by thyroid hormone: Xenopus laevis metamorphosis,” Trends in Endocrinology and Metabolism, vol. 17, no. 2, pp. 40–47, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Rolfe, L. E. McLeod, P. F. Pratt, and C. G. Proud, “Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2),” Biochemical Journal, vol. 388, no. 3, pp. 973–984, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Pantos, C. Xinaris, I. Mourouzis et al., “Thyroid hormone receptor α1: a switch to cardiac cell “metamorphosis”?” Journal of Physiology and Pharmacology, vol. 59, no. 2, pp. 253–269, 2008. View at Google Scholar · View at Scopus
  20. C. Pantos, I. Mourouzis, G. Galanopoulos et al., “Thyroid hormone receptor 1 downregulation in postischemic heart failure progression: the potential role of tissue hypothyroidism,” Hormone and Metabolic Research, vol. 42, no. 10, pp. 718–724, 2010. View at Publisher · View at Google Scholar
  21. K. Kinugawa, M. Y. Jeong, M. R. Bristow, and C. S. Long, “Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor α1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase,” Molecular Endocrinology, vol. 19, no. 6, pp. 1618–1628, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Tavi, M. Sjögren, P. K. Lunde et al., “Impaired Ca2+ handling and contraction in cardiomyocytes from mice with a dominant negative thyroid hormone receptor α,” Journal of Molecular and Cellular Cardiology, vol. 38, no. 4, pp. 655–663, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Pantos, I. Mourouzis, and D. V. Cokkinos, “Thyroid hormone as a therapeutic option for treating ischaemic heart disease: from early reperfusion to late remodelling,” Vascular Pharmacology, vol. 52, no. 3-4, pp. 157–165, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. K. K. Henderson, S. Danzi, J. T. Paul, G. Leya, I. Klein, and A. M. Samarel, “Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure,” Circulation: Heart Failure, vol. 2, no. 3, pp. 243–252, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. F. Chen, S. Kobayashi, J. Chen et al., “Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats,” Journal of Molecular and Cellular Cardiology, vol. 44, no. 1, pp. 180–187, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Pantos, I. Mourouzis, K. Markakis et al., “Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats,” European Journal of Cardio-thoracic Surgery, vol. 32, no. 2, pp. 333–339, 2007. View at Publisher · View at Google Scholar
  27. C. Pantos, I. Mourouzis, K. Markakis, N. Tsagoulis, M. Panagiotou, and D. V. Cokkinos, “Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats,” Basic Research in Cardiology, vol. 103, no. 4, pp. 308–318, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Forini, V. Lionetti, H. Ardehali et al., “Early long-term L-T3 replacement rescues mitochondria and prevents ischemic cardiac remodelling in rats,” Journal of Cellular and Molecular Medicine, vol. 15, no. 3, pp. 514–524, 2011. View at Publisher · View at Google Scholar
  29. C. Kalofoutis, I. Mourouzis, G. Galanopoulos et al., “Thyroid hormone can favorably remodel the diabetic myocardium after acute myocardial infarction,” Molecular and Cellular Biochemistry, vol. 345, no. 1-2, pp. 161–169, 2010. View at Publisher · View at Google Scholar
  30. C. Pantos, I. Mourouzis, N. Tsagoulis et al., “Thyroid hormone at supra-physiological dose optimizes cardiac geometry and improves cardiac function in rats with old myocardial infarction,” Journal of Physiology and Pharmacology, vol. 60, no. 3, pp. 49–56, 2009. View at Google Scholar · View at Scopus
  31. A. W. Linnane and H. Eastwood, “Cellular redox regulation and prooxidant signaling systems: a new perspective on the free radical theory of aging,” Annals of the New York Academy of Sciences, vol. 1067, no. 1, pp. 47–55, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. A. S. R. Araujo, P. Schenkel, A. T. Enzveiler et al., “The role of redox signaling in cardiac hypertrophy induced by experimental hyperthyroidism,” Journal of Molecular Endocrinology, vol. 41, no. 5-6, pp. 423–430, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Pantos, Ch. Xinaris, I. Mourouzis, V. Malliopoulou, E. Kardami, and D. V. Cokkinos, “Thyroid hormone changes cardiomyocyte shape and geometry via ERK signaling pathway: potential therapeutic implications in reversing cardiac remodeling?” Molecular and Cellular Biochemistry, vol. 297, no. 1-2, pp. 65–72, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Pantos, V. Malliopoulou, I. Mourouzis et al., “Thyroxine pretreatment increases basal myocardial heat-shock protein 27 expression and accelerates translocation and phosphorylation of this protein upon ischaemia,” European Journal of Pharmacology, vol. 478, no. 1, pp. 53–60, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Pantos, V. Malliopoulou, I. Mourouzis et al., “Hyperthyroid hearts display a phenotype of cardioprotection against ischemic stress: a possible involvement of heat shock protein 70,” Hormone and Metabolic Research, vol. 38, no. 5, pp. 308–313, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. C. I. Pantos, V. A. Malliopoulou, I. S. Mourouzis et al., “Long-term thyroxine administration protects the heart in a pattern similar to ischemic preconditioning,” Thyroid, vol. 12, no. 4, pp. 325–329, 2002. View at Google Scholar · View at Scopus
  37. A. Shulga, A. Blaesse, K. Kysenius et al., “Thyroxin regulates BDNF expression to promote survival of injured neurons,” Molecular and Cellular Neuroscience, vol. 42, no. 4, pp. 408–418, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. G. J. Kahaly and W. H. Dillmann, “Thyroid hormone action in the heart,” Endocrine Reviews, vol. 26, no. 5, pp. 704–728, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Biondi and D. S. Cooper, “The clinical significance of subclinical thyroid dysfunction,” Endocrine Reviews, vol. 29, no. 1, pp. 76–131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. I. Klein and K. Ojamaa, “Thyroid hormone and the cardiovascular system,” The New England Journal of Medicine, vol. 344, no. 7, pp. 501–509, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Gomberg-Maitland and W. H. Frishman, “Thyroid hormone and cardiovascular disease,” American Heart Journal, vol. 135, no. 2, pp. 187–196, 1998. View at Publisher · View at Google Scholar · View at Scopus
  42. M. A. Hamilton, L. W. Stevenson, M. Luu, and J. A. Walden, “Altered thyroid hormone metabolism in advanced heart failure,” Journal of the American College of Cardiology, vol. 16, no. 1, pp. 91–95, 1990. View at Google Scholar · View at Scopus
  43. C. Opasich, F. Pacini, N. Ambrosino et al., “Sick euthyroid syndrome in patients with moderate-to-severe chronic heart failure,” European Heart Journal, vol. 17, no. 12, pp. 1860–1866, 1996. View at Google Scholar · View at Scopus
  44. A. Pingitore, P. Landi, M. C. Taddei, A. Ripoli, A. L'Abbate, and G. Iervasi, “Triiodothyronine levels for risk stratification of patients with chronic heart failure,” American Journal of Medicine, vol. 118, no. 2, pp. 132–136, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. D. D. Ascheim and K. Hryniewicz, “Thyroid hormone metabolism in patients with congestive heart failure: the low triiodothyronine state,” Thyroid, vol. 12, no. 6, pp. 511–515, 2002. View at Google Scholar · View at Scopus
  46. L. Wartofsky and K. D. Burman, “Alterations in thyroid function in patients with systemic illness: the “euthyroid sick syndrome”,” Endocrine Reviews, vol. 3, no. 2, pp. 164–217, 1982. View at Google Scholar · View at Scopus
  47. R. D. Utiger, “Altered thyroid function in nonthyroidal illness and surgery. To treat or not to treat?” The New England Journal of Medicine, vol. 333, no. 23, pp. 1562–1563, 1995. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Forini, A. Paolicchi, T. Pizzorusso et al., “3,5,3-triiodothyronine deprivation affects phenotype and intracellular [Ca2+]i of human cardiomyocytes in culture,” Cardiovascular Research, vol. 51, no. 2, pp. 322–330, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Friberg, S. Werner, G. Eggertsen, and S. Ahnve, “Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina?” Archives of Internal Medicine, vol. 162, no. 12, pp. 1388–1394, 2002. View at Google Scholar · View at Scopus
  50. E. Galli, A. Pingitore, and G. Iervasi, “The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence,” Heart Failure Reviews, vol. 15, no. 2, pp. 155–169, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. L. Ceremuzyński, A. Górecki, L. Czerwosz et al., “Low serum triiodothyronine in acute myocardial infarction indicates major heart injury,” Kardiologia Polska, vol. 60, no. 5, pp. 468–480, 2004. View at Google Scholar
  52. G. Kozdag, D. Ural, A. Vural et al., “Relation between free triiodothyronine/free thyroxine ratio, echocardiographic parameters and mortality in dilated cardiomyopathy,” European Journal of Heart Failure, vol. 7, no. 1, pp. 113–118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. G. Iervasi, A. Pingitore, P. Landi et al., “Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease,” Circulation, vol. 107, no. 5, pp. 708–713, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Iervasi, S. Molinaro, P. Landi et al., “Association between increased mortality and mild thyroid dysfunction in cardiac patients,” Archives of Internal Medicine, vol. 167, no. 14, pp. 1526–1532, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. P. W. Ladenson, S. I. Sherman, K. L. Baughman, P. E. Ray, and A. M. Feldman, “Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 12, pp. 5251–5255, 1992. View at Publisher · View at Google Scholar · View at Scopus
  56. W. S. Colucci, “Molecular and cellular mechanisms of myocardial failure,” The American Journal of Cardiology, vol. 80, no. 11A, pp. 15L–25L, 1997. View at Google Scholar · View at Scopus
  57. W. I. Khalife, YI. D. Tang, J. A. Kuzman et al., “Treatment of subclinical hypothyroidism reverses ischemia and prevents myocyte loss and progressive LV dysfunction in hamsters with dilated cardiomyopathy,” American Journal of Physiology, vol. 289, no. 6, pp. H2409–H2415, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Tribulova, V. Knezl, A. Shainberg, S. Seki, and T. Soukup, “Thyroid hormones and cardiac arrhythmias,” Vascular Pharmacology, vol. 52, no. 3-4, pp. 102–112, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. I. Klein and S. Danzi, “Thyroid disease and the heart,” Circulation, vol. 116, no. 15, pp. 1725–1735, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. G. J. Kahaly, C. Kampmann, and S. Mohr-Kahaly, “Cardiovascular hemodynamics and exercise tolerance in thyroid disease,” Thyroid, vol. 12, no. 6, pp. 473–481, 2002. View at Google Scholar · View at Scopus
  61. B. Biondi, E. A. Palmieri, S. Fazio et al., “Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 12, pp. 4701–4705, 2000. View at Publisher · View at Google Scholar · View at Scopus
  62. G. J. Kahaly, J. Nieswandt, S. Wagner, J. Schlegel, S. Mohr-Kahaly, and G. Hommel, “Ineffective cardiorespiratory function in hyperthyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 11, pp. 4075–4078, 1998. View at Google Scholar · View at Scopus
  63. L. W. Hu, L. A. Benvenuti, E. A. Liberti, M. S. Carneiro-Ramos, and M. L. M. Barreto-Chaves, “Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling,” American Journal of Physiology, vol. 285, no. 6, pp. R1473–R1480, 2003. View at Google Scholar · View at Scopus
  64. S. P. Barry, S. M. Davidson, and P. A. Townsend, “Molecular regulation of cardiac hypertrophy,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 10, pp. 2023–2039, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. G. Kaminski, D. Michalkiewicz, K. Makowski et al., “Prospective echocardiographic evaluation of patients with endogenous subclinical hyperthyroidism and after restoring euthyroidism,” Clinical Endocrinology, vol. 74, no. 4, pp. 501–507, 2011. View at Publisher · View at Google Scholar
  66. R. M. Abdulrahman, V. Delgado, A. C. T. Ng et al., “Abnormal cardiac contractility in long-term exogenous subclinical hyperthyroid patients as demonstrated by two-dimensional echocardiography speckle tracking imaging,” European Journal of Endocrinology, vol. 163, no. 3, pp. 435–441, 2010. View at Publisher · View at Google Scholar
  67. B. Biondi, “Invited commentary: cardiovascular mortality in subclinical hyperthyroidism: an ongoing dilemma,” European Journal of Endocrinology, vol. 162, no. 3, pp. 587–589, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Vadiveloo, P. T. Donnan, L. Cochrane, and G. P. Leese, “The thyroid epidemiology, audit, and research study (TEARS): the natural history of endogenous subclinical hyperthyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 1, pp. E1–E8, 2011. View at Publisher · View at Google Scholar
  69. J. V. Parle, P. Maisonneuve, M. C. Sheppard, P. Boyle, and J. A. Franklyn, “Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study,” The Lancet, vol. 358, no. 9285, pp. 861–865, 2001. View at Publisher · View at Google Scholar · View at Scopus
  70. F. Osman, M. D. Gammage, and J. A. Franklyn, “Hyperthyroidism and cardiovascular morbidity and mortality,” Thyroid, vol. 12, no. 6, pp. 483–487, 2002. View at Google Scholar · View at Scopus
  71. The Coronary Drug Project Research Group, “The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine,” Journal of the American Medical Association, vol. 220, no. 7, pp. 996–1008, 1972. View at Google Scholar
  72. W. F. Young Jr., C. A. Gorman, N. S. Jiang, D. Machacek, and I. D. Hay, “L-thyroxine contamination of pharmaceutical D-thyroxine: probable cause of therapeutic effect,” Clinical Pharmacology and Therapeutics, vol. 36, no. 6, pp. 781–787, 1984. View at Google Scholar · View at Scopus
  73. M. A. Portman, A. Slee, A. K. Olson et al., “Triiodothyronine supplementation in infants and children undergoing cardiopulmonary bypass (TRICC): a multicenter placebo-controlled randomized trial: age analysis,” Circulation, vol. 122, no. 11, supplement 1, pp. S224–S233, 2010. View at Publisher · View at Google Scholar
  74. J. D. Klemperer, I. Klein, M. Gomez et al., “Thyroid hormone treatment after coronary-artery bypass surgery,” The New England Journal of Medicine, vol. 333, no. 23, pp. 1522–1527, 1995. View at Publisher · View at Google Scholar · View at Scopus
  75. J. D. Klemperer, J. Zelano, R. E. Helm et al., “Triiodothyronine improves left ventricular function without oxygen wasting effects after global hypothermic ischemia,” Journal of Thoracic and Cardiovascular Surgery, vol. 109, no. 3, pp. 457–465, 1995. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Pingitore, E. Galli, A. Barison et al., “Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 4, pp. 1351–1358, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. F. S. Malik, M. R. Mehra, P. A. Uber, M. H. Park, R. L. Scott, and C. H. van Meter, “Intravenous thyroid hormone supplementation in heart failure with cardiogenic shock,” Journal of Cardiac Failure, vol. 5, no. 1, pp. 31–37, 1999. View at Publisher · View at Google Scholar · View at Scopus
  78. M. A. Hamilton, L. W. Stevenson, G. C. Fonarow et al., “Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure,” The American Journal of Cardiology, vol. 81, no. 4, pp. 443–447, 1998. View at Publisher · View at Google Scholar · View at Scopus
  79. P. Moruzzi, E. Doria, and P. G. Agostoni, “Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy,” American Journal of Medicine, vol. 101, no. 5, pp. 461–467, 1996. View at Publisher · View at Google Scholar · View at Scopus
  80. G. Iervasi, M. Emdin, R. M. P. Colzani et al., “Beneficial effects of long-term triiodothyronine (T3) infusion in patients with advanced heart failure and low T3 syndrome,” in Proceedings of the 2nd International Congress on Heart Disease—New Trends in Research, Diagnosis and Treatment, A. Kimchi, Ed., pp. 549–553, Medimond Medical Publications, Washington, DC, USA, 2001. View at Google Scholar
  81. M. G. Trivieri, G. Y. Oudit, R. Sah et al., “Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 15, pp. 6043–6048, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. D. D. Belke, B. Gloss, E. A. Swanson, and W. H. Dillmann, “Adeno-associated virus-mediated expression of thyroid hormone receptor isoforms-α1 and -β1 improves contractile function in pressure overload-induced cardiac hypertrophy,” Endocrinology, vol. 148, no. 6, pp. 2870–2877, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. P. Moruzzi, E. Doria, P. G. Agostoni, V. Capacchione, and P. Sganzerla, “Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy,” The American Journal of Cardiology, vol. 73, no. 5, pp. 374–378, 1994. View at Publisher · View at Google Scholar · View at Scopus
  84. H. Degens, A. J. Gilde, M. Lindhout, P. H. M. Willemsen, G. J. van der Vusse, and M. van Bilsen, “Functional and metabolic adaptation of the heart to prolonged thyroid hormone treatment,” American Journal of Physiology, vol. 284, no. 1, pp. H108–H115, 2003. View at Google Scholar · View at Scopus
  85. E. A. Boehm, B. E. Jones, G. K. Radda, R. L. Veech, and K. Clarke, “Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart,” American Journal of Physiology, vol. 280, no. 3, pp. H977–H983, 2001. View at Google Scholar · View at Scopus
  86. G. D. Pennock, T. E. Raya, J. J. Bahl, S. Goldman, and E. Morkin, “Cardiac effects of 3,5-diiodothyropropionic acid, a thyroid hormone analog with inotropic selectivity,” Journal of Pharmacology and Experimental Therapeutics, vol. 263, no. 1, pp. 163–169, 1992. View at Google Scholar · View at Scopus
  87. X. Wang, W. Zheng, L. P. Christensen, and R. J. Tomanek, “DITPA stimulates bFGF, VEGF, angiopoietin, and Tie-2 and facilitates coronary arteriolar growth,” American Journal of Physiology, vol. 284, no. 2, pp. H613–H618, 2003. View at Google Scholar · View at Scopus
  88. E. Morkin, G. Pennock, P. H. Spooner, J. J. Bahl, K. Underhill Fox, and S. Goldman, “Pilot studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure,” Cardiology, vol. 97, no. 4, pp. 218–225, 2002. View at Google Scholar · View at Scopus
  89. S. Goldman, M. McCarren, E. Morkin et al., “DITPA (3,5-diiodothyropropionic acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study,” Circulation, vol. 119, no. 24, pp. 3093–3100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Pingitore, G. Iervasi, and M. A. Gerdes, “Letter by Pingitore et al regarding article, “DITPA (3,5-diiodothyropropionic acid), a thyroid hormone analog to treat heart failure: phase II trial Veterans Affairs cooperative study“,” Circulation, vol. 121, no. 10, e240, 2010. View at Google Scholar
  91. H. Mizuma, M. Murakami, and M. Mori, “Thyroid hormone activation in human vascular smooth muscle cells: expression of type II iodothyronine deiodinase,” Circulation Research, vol. 88, no. 3, pp. 313–318, 2001. View at Google Scholar · View at Scopus
  92. A. Colantuoni, P. L. Marchiafava, D. Lapi, F. S. Forini, and G. Iervasi, “Effects of tetraiodothyronine and triiodothyronine on hamster cheek pouch microcirculation,” American Journal of Physiology, vol. 288, no. 4, pp. H1931–H1936, 2005. View at Publisher · View at Google Scholar · View at Scopus
  93. A. M. Gerdes and G. Iervasi, “Thyroid replacement therapy and heart failure,” Circulation, vol. 122, no. 4, pp. 385–393, 2010. View at Publisher · View at Google Scholar
  94. J. A. Ezekowitz, P. Kaul, J. A. Bakal, P. W. Armstrong, R. C. Welsh, and F. A. McAlister, “Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction,” Journal of the American College of Cardiology, vol. 53, no. 1, pp. 13–20, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. T. M. Khumri, K. J. Reid, M. Kosiborod, J. A. Spertus, and M. L. Main, “Usefulness of left ventricular diastolic dysfunction as a predictor of one-year rehospitalization in survivors of acute myocardial infarction,” The American Journal of Cardiology, vol. 103, no. 1, pp. 17–21, 2009. View at Publisher · View at Google Scholar · View at Scopus